Trials / Completed
CompletedNCT05294562
China Post-Market Clinical Follow-up of FACILLE®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,552 (actual)
- Sponsor
- SciVision Biotech Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The results showed that subjects tolerated the Sodium Hyaluronate Gel for Injection (FACILLE®) well, with no systemic AEs, SAEs, and unanticipated AEs and associated with high satisfaction and self-evaluated effectiveness. Nearly half of the subjects maintained correction for 12 months and were satisfied with the product 3 years after the first injection.
Conditions
Timeline
- Start date
- 2016-12-14
- Primary completion
- 2017-05-07
- Completion
- 2020-05-12
- First posted
- 2022-03-24
- Last updated
- 2022-03-24
Source: ClinicalTrials.gov record NCT05294562. Inclusion in this directory is not an endorsement.